Patent intelligence · US
US 12377112
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
Patent details — US 12377112
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 5, 2025
- Expiration
- Jul 31, 2045
- Applicant
- Compass Pathfinder Limited
- Claims
- 27
- CPC classes
- A61K, A61K31/4045, A61K31/661, A61K31/675
Quick answer
US 12377112 (Methods of treating neurocognitive disorders, chronic pain and reducing inflammation) is held by Compass Pathfinder Limited. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Compass Pathfinder Limited
- Grant date
- Expiration
- Claims
- 27
- CPC classes
- A61K, A61K31/4045, A61K31/661, A61K31/675, A61K9/0053, A61K9/20
More from Compass Pathfinder Limited
Related pharmaceutical patents in our USPTO index.
-
US 12312375
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 12286483
Method of treating cancer using CD137 antibodies and PD-1 antagonists
granted -
US 12186285
Compositions and methods of treatment for tinea pedis
granted -
US 12070594
Biomedical electrode with anti-microbial properties
granted -
US 11970538
Multispecific binding constructs against checkpoint molecules and uses thereof
granted -
US 11939346
Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
granted -
US 11865179
Progesterone formulations having a desirable PK profile
granted
Frequently asked questions
What is US patent 12377112?
US 12377112 (Methods of treating neurocognitive disorders, chronic pain and reducing inflammation) is held by Compass Pathfinder Limited. Status: granted. Granted Aug 5, 2025. Expires Jul 31, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12377112?
Compass Pathfinder Limited is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 100 pharmaceutical patents for this assignee.
When does US 12377112 expire?
Our index shows an expiration date of Jul 31, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.